Health Catalyst, Inc - HCAT STOCK NEWS

Health Catalyst announced a public offering of 4,245,283 shares of common stock at $53.00 per share, projected to raise approximately $225.0 million in gross proceeds. A 30-day option allows underwriters to purchase an additional 636,792 shares. The offering, led by J.P. Morgan, Goldman Sachs, and Evercore, is expected to close around August 13, 2021, pending customary conditions. This capital will support the company’s goals in healthcare data and analytics.

Health Catalyst has announced a public offering of $225 million in common stock, all of which will be offered by the company itself. The offering is contingent on market conditions and may include an option for underwriters to purchase an additional $33.75 million in shares within 30 days. J.P. Morgan, Goldman Sachs, and Evercore act as joint bookrunning managers for the offering. The public offering is conducted under an effective shelf registration and associated prospectus filed with the SEC.

Twistle by Health Catalyst (Nasdaq: HCAT) will participate in the HIMSS21 Global Conference, scheduled for August 9-13, 2021, in Las Vegas. Twistle plans to showcase its secure patient communication platform at booth #C437-38, highlighting how it can reduce health disparities and improve patient engagement. Attendees can witness live demonstrations and learn about initiatives like the #pinksocks movement, emphasizing community connection. A presentation by Tom Burton will discuss the ROI of patient engagement strategies implemented by Providence, aimed at enhancing surgical outcomes and reducing complications.

Health Catalyst (Nasdaq: HCAT) reported strong Q2 2021 financial results, exceeding revenue and Adjusted EBITDA guidance. The company achieved a positive Adjusted EBITDA of $1.7 million, marking a significant milestone since its inception. Technology revenue rose 39% to $35.5 million, while total revenue increased 38% to $59.6 million compared to Q2 2020. The recent acquisition of Twistle, effective July 1, 2021, is expected to enhance its Population Health analytics offerings. However, the company reported a net loss of $35.8 million, a 32% increase from the previous year.

Health Catalyst, a top provider of data and analytics for healthcare, announced participation in the 41st Annual Canaccord Genuity Growth Stock Conference. CFO Bryan Hunt and SVP Adam Brown will present in a fireside chat on August 11, 2021, at 2:00 p.m. ET. The company is dedicated to using data for healthcare improvements, utilizing a cloud-based platform that processes over 100 million patient records.

Health Catalyst aims for a future where all healthcare decisions are informed by data, enhancing clinical, financial, and operational outcomes.

Health Catalyst (Nasdaq: HCAT) will release its 2021 second quarter operating results on August 5, 2021, after market close. The company will host a conference call at 5 p.m. E.T. that day to discuss the results. Participants can join by calling 1-800-708-4539 (U.S.) or 1-847-619-6396 (international) using the code 50199342. A live audio webcast will be available, with a replay accessible for 90 days afterward. Health Catalyst is known for data and analytics technology that improves clinical, financial, and operational aspects for healthcare organizations.

Health Catalyst (Nasdaq: HCAT) has launched Value Optimizer, a new solution aimed at enhancing value-based care (VBC) performance for healthcare organizations. This technology addresses limitations in traditional population health tools by providing comprehensive data and insights necessary for effective VBC strategy management. Key features include a quantified view of financial opportunities, continually updated data, transparent methodologies for benchmarking, and expert guidance for maximizing performance. This solution aims to help healthcare providers lower costs while maintaining the quality of care.

Health Enterprise Partners (HEP) announced five realizations of portfolio companies and a new investment in Kno2, marking its tenth platform investment from HEP III. HEP focuses on founder-financed businesses, having previously invested in Twistle, which enhances patient engagement in healthcare. Health Catalyst (NASDAQ: HCAT) disclosed its acquisition of Twistle, enhancing its data and analytics services. Privia Health (NASDAQ: PRVA) completed a successful IPO, raising approximately $131.7 million. HEP's new investment in Kno2 will support interoperability in healthcare, aiming for better patient information exchange.

Health Catalyst (Nasdaq: HCAT) announced a definitive agreement to acquire Twistle, a patient engagement SaaS company based in Albuquerque, New Mexico. The acquisition aims to enhance patient-centered communication and improve healthcare outcomes by integrating Twistle’s workflow technology with Health Catalyst's data platform, DOS™. The transaction is expected to close in early Q3 2021 and will be funded through a mix of stock and cash. The synergy aims to drive better care and reduce costs, aligning with Health Catalyst's mission to leverage data for healthcare improvements.